drugset / Trial / NCT02456532

Safety and Efficacy of Chronic Hypnotic Use 2

NCT02456532

Phase 4 Completed 41 enrolled Henry Ford Health System
RandomizedParallel-groupTriple-blindTreatment

Summary

This proposal will assess risks for transition from therapeutic hypnotic use to abuse in people with insomnia. The investigators will study a hypothesized at-risk sub-population, insomniacs with hyperarousal, and compare two hypnotics, a drug with mood effects, eszopiclone, versus one without mood effects, zolpidem.

Timeline

Start
2015-08-05
Primary completion
2022-02-22
Completion
2022-02-22

Drugs

EvaluationDrugModalityDoseRoute
Comparator Eszopiclone Small molecule 3 mg
Comparator Zolpidem Small molecule 12.5 mg

Indications